

# INDEX

- I. WG McBride  
*Thalidomide and congenital abnormalities.*  
Lancet 1961; ii: 1358-1358 . . . . . 1
- II. DJ Finney  
*The design and logic of a monitor of drug use.*  
J Chron Dis 1965; 18: 77-98 . . . . . 5
- III. WHW Inman, MP Vessey, B Westerholm, A Engelund  
*Thromboembolic disease and the steroid content of oral contraceptives:*  
*A report to the Committee on Safety of Drugs.*  
Br Med J 1970; 2: 203-209. . . . . 29
- IV. AL Herbst, H Ulfelder, DC Poskanzer  
*Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women*  
N Engl J Med 1971; 284: 878-881 . . . . . 39
- V. Boston Collaborative Drug Surveillance Group  
*Regular aspirin intake and acute myocardial infarction.*  
Br Med J 1974; 1: 440-443. . . . . 45
- VI. OS Miettinen  
*Confounding and effect-modification.*  
Am J Epidemiol 1974; 100: 350-353 . . . . . 51
- VII. D Slone, S Shapiro, OS Miettinen, WD Finkle, PD Stolley  
*Drug evaluation after marketing.*  
Ann Intern Med 1979; 90: 257-261 . . . . . 57
- VIII. PR Rosenbaum, DB Rubin  
*The central role of the propensity score in observational studies for causal effects.*  
Biometrika 1983; 70: 41-55 . . . . . 65
- IX. BL Strom, OS Miettinen, KL Melmon  
*Postmarketing studies of drug efficacy: How?*  
Am J Med 1984; 77: 703-708 . . . . . 83
- X. The International Agranulocytosis and Aplastic Anemia Study  
*Risks of agranulocytosis and aplastic anemia.*  
*A first report of their relation to drug use with special reference to analgesics.*  
JAMA 1986; 256: 1749-1757 . . . . . 91

## INDEX

- XI. WA Ray, MR Griffin, W Schaffner, DK Baugh, LJ Melton  
*Psychotropic drug use and the risk of hip fracture.*  
N Engl J Med 1987; 316: 363-369 . . . . . 103
- XII. J Crane, N Pearce, A Flatt, C Burgess, R Jackson,  
T Kwong, M Ball, R Beasley  
*Prescribed fenoterol and death from asthma in New Zealand,  
1981-83: Case-control study.*  
Lancet 1989; i: 917-922 . . . . . 113
- XIII. S Shapiro  
*The role of automated record linkage in the  
postmarketing surveillance of drug safety: A critique.*  
Clin Pharmacol Ther 1989; 46: 371-386 . . . . . 121
- XIV. GA Faich, BV Stadel  
*The future of automated record linkage for  
postmarketing surveillance: A response to Shapiro.*  
Clin Pharmacol Ther 1989; 46: 387-389 . . . . . 139
- XV. M Maclure  
*The case-crossover design: A method for studying transient effects  
on the risk of acute events.*  
Am J Epidemiol 1991; 133: 144-153 . . . . . 145
- XVI. MR Griffin, JM Piper, JR Daugherty, M Snowden, WA Ray  
*Nonsteroidal anti-inflammatory drug use and increased risk  
for peptic ulcer disease in elderly persons.*  
Ann Intern Med 1991; 114: 257-263 . . . . . 157
- XVII. H Jick, SS Jick, LE Derby  
*Validation of information recorded on general practitioner  
based computerized data resource in the United Kingdom.*  
Br Med J 1991; 302: 766-768 . . . . . 167
- XVIII. WO Spitzer, S Suissa, P Ernst, RI Horwitz, B Habbick,  
D Cockcroft, JF Boivin, M McNutt, AS Buist, AS Rebuck  
*The use of beta-agonists and the risk of death  
and near death from asthma.*  
N Engl J Med 1992; 326: 501-506 . . . . . 173
- XIX. S Pérez Gutthann, LA García Rodríguez  
*The increased risk of hospitalizations for acute liver injury  
in a population with exposure to multiple drugs.*  
Epidemiology 1993; 4: 496-501 . . . . . 181
- XX. LAG Rodríguez, H Jick  
*Risk of upper gastrointestinal bleeding and perforation associated  
with individual non-steroidal anti-inflammatory drugs.*  
Lancet 1994; 343: 769-772 . . . . . 189
- XXI. MJS Langman, J Weil, P Wainwright, DH Lawson, MD Rawlins,  
RFA Logan, M Murphy, MP Vessey, DG Colin-Jones  
*Risk of bleeding peptic ulcer associated  
with individual non-steroidal anti-inflammatory drugs.*  
Lancet 1994; 343: 1075-1078 . . . . . 195

- XXII. S Suissa  
*The case-time-control design.*  
Epidemiology 1995; 6: 248-253. . . . . 201
- XXIII. H Jick, SS Jick, V Gurewich, M Myers, C Vasilakis  
*Risk of idiopathic cardiovascular death  
and nonfatal venous thromboembolism in women  
using oral contraceptives with differing progestagen components.*  
Lancet 1995; 346: 1589-1593 . . . . . 209
- XXIV. WO Spitzer, MA Lewis, LAJ Heinemann, M Thorogood,  
KD MacRae  
*Third generation oral contraceptives and risk of venous  
thromboembolic disorders: An international case-control study.*  
Br Med J 1996; 312: 83-88 . . . . . 217
- XXV. L Abenham, Y Moride, F Brenot, S Rich, J Benichou,  
X Kurz, T Higenbottam, C Oakley, E Wouters, M Aubier,  
G Simonneau, B Begaud  
*Appetite-suppressant drugs and the risk  
of primary pulmonary hypertension.*  
N Engl J Med 1996; 335: 609-616 . . . . . 225
- XXVI. H Jick, C Vasilakis, LA Weinrauch, CR Meier, SS Jick, LE Derby  
*A population-based study of appetite-suppressant drugs  
and the risk of cardiac-valve regurgitation.*  
N Engl J Med 1998; 339: 719-724 . . . . . 235
- XXVII. RDT Farmer, RA Lawrenson, JC Todd, TJ Williams, KD MacRae,  
F Tyrer, GM Leydon  
*A comparison of the risks of venous thromboembolic disease  
in association with different combined oral contraceptives.*  
Br J Clin Pharmacol 2000; 49: 580-590 . . . . . 243